Acumen Pharmaceuticals Management
Management criteria checks 2/4
Acumen Pharmaceuticals' CEO is Dan O'Connell, appointed in Dec 2014, has a tenure of 9.42 years. total yearly compensation is $3.93M, comprised of 15.2% salary and 84.8% bonuses, including company stock and options. directly owns 0.042% of the company’s shares, worth $82.06K. The average tenure of the management team and the board of directors is 2.5 years and 5.6 years respectively.
Key information
Dan O'Connell
Chief executive officer
US$3.9m
Total compensation
| CEO salary percentage | 15.2% |
| CEO tenure | 9.4yrs |
| CEO ownership | 0.04% |
| Management average tenure | 2.5yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
Sep 28Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
Jun 30We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$4m | US$598k | -US$52m |
| Sep 30 2023 | n/a | n/a | -US$49m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$3m | US$570k | -US$43m |
| Sep 30 2022 | n/a | n/a | -US$38m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$1m | US$525k | -US$101m |
| Sep 30 2021 | n/a | n/a | -US$93m |
| Jun 30 2021 | n/a | n/a | -US$92m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$336k | US$240k | -US$7m |
Compensation vs Market: Dan's total compensation ($USD3.93M) is above average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.
CEO
Dan O'Connell (53 yo)
9.4yrs
Tenure
US$3,930,011
Compensation
Mr. Daniel J. O’Connell, also known as Dan, MBA was a Key Advisor at Acidophil, LLC. He served as President until February 01, 2024 and serves as Chief Executive Officer of Acumen Pharmaceuticals, Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9.4yrs | US$3.93m | 0.042% $ 82.1k | |
| CFO & Chief Business Officer | 3yrs | US$1.61m | 0.14% $ 267.6k | |
| Chief Legal Officer & Corporate Secretary | 1.7yrs | US$1.48m | 0.18% $ 350.5k | |
| President & Chief Development Officer | less than a year | no data | no data | |
| Co-Founder | 28.3yrs | US$42.00k | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Chief Operating Officer | 3.3yrs | US$223.68k | 0.16% $ 311.9k | |
| Vice President | less than a year | no data | no data | |
| VP & Head of Investor Relations | 1.7yrs | no data | no data | |
| Associate Director of Communications | 2yrs | no data | no data | |
| Executive VP & Head of Human Resources | 3.3yrs | no data | no data |
2.5yrs
Average Tenure
54yo
Average Age
Experienced Management: ABOS's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 18.1yrs | US$3.93m | 0.042% $ 82.1k | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman of the Board | 5.6yrs | US$173.52k | 0.51% $ 978.6k | |
| Independent Director | 2.1yrs | US$152.27k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 10yrs | US$141.02k | no data | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.5yrs | US$147.52k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | no data | no data |
5.6yrs
Average Tenure
63.5yo
Average Age
Experienced Board: ABOS's board of directors are considered experienced (5.6 years average tenure).